Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Third of three parts
The Inflation Reduction Act (IRA) of 2022 contains some of the most significant changes in healthcare regulation since the introduction of the Medicare Modernization Act of 2003. There are many healthcare-related policy changes contained in the IRA, which can be categorized into three major sections: expansion of patient access to affordable insurance, adjustments to medication pricing and reimbursement and reforms to patient cost sharing.
You can read the first two installments of our review of the IRA here and here.
In this installment, we are covering several reforms to patient cost-sharing for Medicare Part D Plans (PDP) and Medicare Advantage Prescription Drug (MA-PD) Plans.
Patient cost sharing for Medicare Part D drugs has gone through a variety of revisions since the introduction of the Medicare Modernization Act in 2003. Many changes have focused on reducing or eliminating the donut hole where consumers were initially responsible for the full payment of medications. However, patients have always been responsible for 5% co-insurance once they reached the catastrophic phase of their benefit. The IRA will remove patient responsibility for the catastrophic phase starting in 2024. Further, in 2025 the IRA will establish an annual out-of-pocket cap of $2,000 for all Part D beneficiaries and will finally eliminate the “donut hole” such that there is only an initial coverage phase from a patient perspective.
To assist in paying for these changes to patient out-of-pocket costs the IRA will sunset the existing Medicare Coverage Gap Discount Program and create a new discount program which will require manufacturers to pay a 10% rebate in the initial coverage phase and a 20% rebate in the catastrophic phase. Similar to the previous program, these rebates will apply to branded drugs, biologics, and biosimilars on the Part D benefit. It also appears that these rebates will apply to drugs that have negotiated a maximum fair price, further eroding net price.
At the start of each year, PDP and MA-PD beneficiaries who are taking high-cost medications typically see a significant out-of-pocket burden as they pay their deductible during initial coverage and in the coverage gap. As part of the IRA, starting in 2025, consumers can smooth their out-of-pocket expenses over the course of the year. This would be implemented at any point in the year by dividing the amount of money the beneficiary owes the plan sponsor by the remaining months in the year. Pharmacies would still be paid in full by the plan sponsor at the time of sale. If a beneficiary fails to pay their smoothed out-of-pocket costs in any month, their participation in the cost smoothing program would be terminated, they would owe the full out-of- pocket cost amount, and they would not be allowed to participate in the cost-smoothing program in the next year. This smoothing of cost-sharing is expected to ease payment for many patients, especially those living on fixed incomes.
The rising cost of insulin to consumers has been a target of criticism in recent years; the IRA seeks to limit insulin out-of-pocket costs for Medicare beneficiaries. For the plan years of 2023 and 2024, the standard Part D deductible will not apply to insulin and insulin out-of-pocket cost will be limited to $35 per month. Starting in 2025, the deductible will apply, but cost sharing will remain limited to $35 per month. Finally, in 2026 and beyond, cost sharing will be limited to the lesser of:
Most vaccines are covered under Medicare Part D with the major exceptions of influenza, pneumonia, hepatitis B, COVID-19, and post-exposure prophylaxis vaccines (e.g., tetanus and rabies) all of which are covered under Medicare Part B. There are already provisions which ensure that vaccines provided under Medicare Part B have no patient cost-sharing, but that has typically been untrue for vaccines covered under Medicare Part D. The IRA eliminated cost- sharing for Part D covered vaccines that have been recommended by the Advisory Committee on Immunization Practices (ACIP). It further provides a temporary (2023-2025) subsidy to plans to assist in paying for the expected increased uptake of vaccinations for Medicare beneficiaries.
In summary, the IRA provides several mechanisms to help reduce the out-of-pocket burden on Medicare Part D and Medicare Advantage Prescription Drug Plan beneficiaries.
Matthew Majewski and Rhett Johnson are vice presidents in the Life Sciences Practice at Charles River Associates, a global consulting firm.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More